4-碘-5-甲基异噁唑-3-胺 | 930-85-8

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 中文名称: 4-碘-5-甲基异噁唑-3-胺
• 中文别名: 3-氨基-4-碘-5-甲基异恶唑
• 英文名称: 3-amino-4-iodo-5-methylisoxazole
• 英文别名: 4-iodo-5-methyl-isoxazol-3-ylamine；3-Amino-4-iod-5-methyl-isoxazol；3-Amino-4-jod-5-methyl-isoxazol；3-Amino-4-iod-5-methylisoxazol；3-Amino-4-jod-5-methylisoxazol；4-Jod-5-methyl-3-aminoisoxazol；4-Iodo-5-methylisoxazol-3-amine；4-iodo-5-methyl-1,2-oxazol-3-amine
• CAS: 930-85-8
• 化学式: C₄H₅IN₂O
• 分子量: 224.001
• InChiKey: ABSKCUUMSKWKSW-UHFFFAOYSA-N

物化性质

• 熔点：
  104.0-104.5℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-碘-5-甲基异噁唑-3-胺 、 甲基磺酰氯 以 吡啶 为溶剂， 反应 5.0h， 生成 3-Methansulfonylamino-4-jod-5-methyl-isoxazol
  参考文献：
  名称：

  [异恶唑的衍生物。二。N-1-酰基磺酰二唑的合成，结构及其同系物]

  摘要：

  3-amino-4-halo-5-methyl-isoxazol 的双磺酰基衍生物的结构被化学证实为 3 位上相应的双磺酰基亚胺，不可能是 2-(2-磺酰基)-3-halo-5-methyl-isoxazolin-4-like 化合物。本研究提出了一种以 4-硝基-N-(5-甲基-3-异恶唑基)-苯磺酰胺为起点，通过碘化、酰化和硝基还原伯胺等步骤制备 N1-乙酰化或苯甲酰化磺胺碘唑的新方法。

  DOI：

  10.1248/cpb.14.280
• 作为产物：
  描述：

  3-氨基-5-甲基异恶唑 在 N-碘代丁二酰亚胺 、 溶剂黄146 作用下， 反应 0.5h， 生成 4-碘-5-甲基异噁唑-3-胺
  参考文献：
  名称：

  Energetic and topological approach for characterization of supramolecular clusters in organic crystals

  摘要：

  在这项工作中，提出了一种方法来理解有机化合物的晶体排列。

  DOI：

  10.1039/c4ra06040g

文献信息

• N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate
  申请人：Immunopharmaceutics, Inc.

  公开号：US05514691A1

  公开（公告）日：1996-05-07

  N-(4-halo-isoxazolyl)sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(4-halo-3-isoxazolyl)sulfonamides and N-(4-halo-5-isoxazolyl)benzenesulfonamides and methods for inhibiting the binding of an endothelin peptide to an endothelin receptor or increasing the activity of endothelin peptides by contacting the receptor with a sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

  提供了N-(4-卤异噁唑基)磺胺类化合物以及调节或改变内皮素家族肽活性的方法。具体包括N-(4-卤-3-异噁唑基)磺胺类化合物和N-(4-卤-5-异噁唑基)苯磺胺类化合物，以及通过将受体与磺胺类化合物接触来抑制内皮素肽与内皮素受体结合或增加内皮素肽活性的方法。还提供了通过给予这些磺胺类化合物或其前药的有效剂量来治疗内皮素介导的疾病的方法。
• Sulfonamides and derivatives thereof that modulate the activity of
  申请人：Texas Biotechnology Corporation

  公开号：US05571821A1

  公开（公告）日：1996-11-05

  Sulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided. The sulfonamides have formula I: ##STR1## in which Ar.sup.1 is a 3- or 5-isoxazolyl and Ar.sup.2 is selected from among alkyl, including straight and branched chains, aromatic rings, fused aromatic rings and heterocyclic rings, including 5-membered heterocycles with one, two or more heteroatoms and fused ring analogs thereof and 6-membered rings with one, two or more heteroatoms and fused ring analogs thereof. Ar.sup.2 is preferably thiophenyl, furyl, pyrrolyl, naphthyl, and phenyl. Compounds in which Ar.sup.1 is a 4-halo-substituted isoxazole are more active than the corresponding alkyl-substituted compound and compounds in which Ar.sup.1 is substituted at this position with a higher alkyl tend to exhibit greater affinity for ET.sub.B receptors than the corresponding lower alkyl-substituted compound.

  磺胺类药物及使用这些磺胺类药物抑制内皮素肽与内皮素受体结合的方法是通过将磺胺类药物与受体接触来实现的。还提供了通过给予有效剂量的这些磺胺类药物或其前药来治疗内皮素介导的疾病的方法，这些药物能够抑制或增加内皮素的活性。这些磺胺类药物的化学式为I：##STR1## 其中Ar.sup.1是3-或5-异噁唑基，Ar.sup.2从烷基（包括直链和支链）、芳香环、融合芳香环和杂环中选择，包括含有一个、两个或更多杂原子的5元杂环及其融合环类似物，以及含有一个、两个或更多杂原子的6元环及其融合环类似物。Ar.sup.2最好是噻吩基、呋喃基、吡咯基、萘基和苯基。Ar.sup.1为4-卤代异噁唑基的化合物比相应的烷基取代化合物更活跃，而Ar.sup.1在这个位置被更高烷基取代的化合物倾向于表现出对ET.sub.B受体更大的亲和力，而不是相应的较低烷基取代的化合物。
• Proposal for crystallization of 3-amino-4-halo-5-methylisoxazoles: an energetic and topological approach
  作者：M. A. P. Martins、A. R. Meyer、A. Z. Tier、K. Longhi、L. C. Ducati、H. G. Bonacorso、N. Zanatta、C. P. Frizzo

  DOI：10.1039/c5ce01295c

  日期：——

  The supramolecular structure of 3-amino-4-halo-5-methylisoxazoles (halo = Cl, Br, and I) was investigated in order to suggest a route for crystallization of organic molecules.

  研究了3-氨基-4-卤代-5-甲基异噁唑（卤代物为Cl、Br和I）的超分子结构，以便提出有机分子结晶的途径。
• Benzenesulfonamides and the use thereof to modulate the activity of endothelin
  申请人：Texas Biotechnology Corporation

  公开号：US06376523B1

  公开（公告）日：2002-04-23

  N-(5-isoxazolyl)benzenesulfonamides and N-(3-isoxazolyl)benzenesulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(5-isoxazolyl)biphenylsulfonamides and N-(3-isoxazolyl)biphenylsulfonamides and methods for inhibiting the binding of an endothelin peptide to an endothelin receptor or increasing the activity of endothelin peptides by contacting the receptor with a sulfonamide are provided. N-isoxzolyl-4-biphenylsulfonamides are particularly preferred. These compounds exhibit activity as endothelin receptor B antagonists. Methods for treating endothelin-mediated disorders, particularly inflammatory diseases, such as asthma, by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

  本发明提供了N-(5-异噁唑基)苯磺酰胺和N-(3-异噁唑基)苯磺酰胺及其方法，用于调节或改变内皮素家族肽的活性。具体地，本发明提供了N-(5-异噁唑基)联苯磺酰胺和N-(3-异噁唑基)联苯磺酰胺及其方法，通过与磺酰胺接触来抑制内皮素肽与内皮素受体的结合或增加内皮素肽的活性。N-异噁唑基-4-联苯磺酰胺是特别优选的。这些化合物表现出内皮素受体B拮抗剂的活性。本发明还提供了通过给予这些磺酰胺或其前药的有效剂量来治疗内皮素介导的疾病，特别是炎症性疾病，如哮喘的方法，以抑制或增加内皮素的活性。